万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>生物科学>>生化与分子生物学
您的位置:万维书刊网 >>sci/e期刊大全 >>生物科学>>生物学
您的位置:万维书刊网 >>sci/e期刊大全 >>生物科学>>细胞生物学

FASEB JOURNAL《美国实验生物学会联合会会志》 (官网投稿)

简介
  • 期刊简称FASEB J
  • 参考译名《美国实验生物学会联合会会志》
  • 核心类别 SCIE(2023版), 外文期刊,
  • IF影响因子4.966
  • 自引率3.30%
  • 主要研究方向生物学-BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学;BIOLOGY 生物学;CELL BIOLOGY 细胞生物学

主要研究方向:

等待设置主要研究方向
生物学-BIOCHEMISTRY & MOLECULAR BIOLOGY 生化与分子生物学;BIOLOGY 生物学;CELL BIOLOGY 细胞生物学

FASEB JOURNAL《美国实验生物学会联合会会志》(月刊). The FASEB Journal publishes international, transdisciplinary research covering all fields of biology at every&n...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:

https://faseb.onlinelibrary.wiley.com/journal/15306860

3、投稿网址:https://fasebj.msubmit.net/

4、官网邮箱:journals@faseb.org

5、期刊刊期:月刊,一年出版十二期。

2021416日星期五

                              

 

投稿须知【官网信息】

 

AUTHOR GUIDELINES

Sections

Submission

Aims and Scope

Manuscript Categories and Requirements

Preparing the Submission

Editorial Policies and Ethical Considerations

Author Licensing

Publication Process After Acceptance

Post Publication

Editorial Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium, and that all authors accept full responsibility for the execution of the study, had full access to all the data, and agree with the decision to publish the submitted work.

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://fasebj.msubmit.net

For help, please contact Mary Kiorpes Hayden: journals@faseb.org

Data protection:

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

The FASEB Journal preprint policy:

This journal will consider for review articles previously available as preprints on non-commercial servers such as ArXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, etc. Authors may also post the submitted version of a manuscript to non-commercial servers at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

FASEB permits the submission of preprint manuscripts, which will undergo the same review process as "non-preprint" manuscripts. Preprint submissions must meet the following criteria and conditions:

The preprint cannot be under consideration for publication elsewhere at any time it is being considered for publication by FASEB.

Once a manuscript has been formally submitted to FASEB, no additional versions of the manuscript may be posted to preprint servers (A) while it is under consideration or reconsideration, (B) while undergoing revision prior to, or during, re-review/resubmission, and (C) while being prepared for publication.

Additional manuscript versions of articles published in The FASEB Journal may not be posted to preprint servers after publication unless these manuscripts have an open access copyright license.

The preprint must be assigned a preprint DOI, and the preprint server must make all versions of a preprint manuscript (and related materials, such as figures, tables, supplemental data, etc.) available, as well as make it clear which version is the latest version.

The preprint server must automatically link to the article in the journal once the article has been published on the Journal's website.

Preprint submissions posted to preprint servers with an open access license are allowed, but authors will be required—without exception—to pay the Journal's Article Publication Fee as a condition of acceptance.

The authors must: (A) disclose at first submission that a manuscript has been posted to a preprint server, (B) indicate which server is being used and the copyright license under which the manuscript has been posted, and (C) provide a link to the preprint version of the article.

Once a preprint manuscript has been formally submitted, the authors may not change the copyright terms of the preprint.

Failure to meet these criteria and conditions may result in the disqualification of a submission at any stage, resulting in immediate rejection. In addition, the Journal reserves the right—but is not obligated—to consider the comments made to manuscripts posted to preprint servers and factor these comments into final decisions at any stage of the peer review process.

For help with submissions, please contact Mary Kiorpes Hayden at journals@faseb.org

2. AIMS AND SCOPE

The FASEB Journal publishes international, transdisciplinary research covering all fields of biology at every level of organization: atomic, molecular, cell, tissue, organ, organismic and population. While the journal strives to include research that cuts across the biological sciences, it also considers submissions that lie within one field, but may have implications for other fields as well. The journal seeks to publish basic and translational research, but also welcomes reports of pre-clinical and early clinical research. In addition to research, review, and hypothesis submissions, The FASEB Journal also seeks perspectives, commentaries, book reviews, and similar content related to the life sciences in its Up Front section.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

The FASEB Journal accepts four types of submissions. These are research, review, hypothesis, and up-front articles. Manuscripts should be written in concise, logical, and grammatically correct English. The Editors reserve the right to require correction of manuscripts not written in clear and concise English expository prose. To prevent publication delays, some authors may want to consider having their manuscripts edited by native English speakers prior to submission. Standard nomenclature should be used, whenever possible. Nonstandard abbreviations should be provided in a separate list.

Information about each type is as follows:

Research articles should present original, sound investigations and new research findings in any area of biology.  Reports of negative results are welcome.  Authors are encouraged to include relevance to the advancement of science.  Research articles should include the following sections:  Abstract, Introduction, Materials and Methods, Results, Discussion, and Reference. should be written in concise, logical, and grammatically correct English. The Editors reserve the right to require correction of manuscripts not written in clear and concise English expository prose. To prevent publication delays, some authors may want to consider having their manuscripts edited by native English speakers prior to submission. Standard nomenclature should be used, whenever possible. See below for specific guidance on how research articles should be prepared.

Review articles are usually, but not necessarily, divided into sections, such as Background, Recent Results, Matters of Controversy / Unanswered Questions, and Prospects and Predictions. The bulk of the review should focus on recent findings (within the last two years), with the most attention given to results that break new ground or provide new interpretations of existing dogma. Matters of controversy and unanswered questions should not be overlooked. Authors should also take the opportunity to speculate on the most fruitful directions for future research, possibly even offering predictions of experiments now in progress, either their own or others.

Hypothesis articles propose an explanation of a particular biologic phenomenon. These submissions should include possible ways to test the hypothesis as well as a review of ongoing research being done that may support or not support it.

Methods articles focus on new techniques or innovations related to any of the areas of research covered in the Journal. The description of the method must be complete, with sufficient detail to enable a reader to completely replicate it. Articles that constitute only a small refinement in an existing method will likely be rejected. See below for specific guidance on how methods articles should be prepared.

Up front articles include essays, editorial, book reviews, opinions, perspectives, etc. Articles published in this section are mostly invited by the editors, but The FASEB Journal does permit submissions to this section without invitation.

Experimental Biology Abstracts: The FASEB Journal publishes abstracts from Experimental Biology meetings in a supplemental issue once a year. This supplemental issue is only available online. Supplemental issues prior to 2006 are only available in print and must be obtained through your institution’s library. Meeting abstracts are not peer-reviewed and are not under the regulation of The FASEB Journal’s editorial board.

4. PREPARING THE SUBMISSION

Manuscript Formatting: Manuscripts should fit on 8.5 x 11 inch paper, have .5 inch margins with 1.5 line spacing. Font should be 12-point Times New Roman. Pages should be numbered. Every effort should be made to be brief, short of skipping essential data or methods. Use a common word processing program such as MS Word, Google Docs, etc. to prepare the file. Left-justify the text and do not use automatic end-of-line hyphenation.

Cover Letters

Manuscripts submitted to The FASEB Journal should have a cover letter. This letter introduces the work to the editors and explains why it is of interest to the journal's readers. It should also contain disclosures or statements relevant to the submission, such as explanations surrounding conflicts of interest or potential conflicts of interest. In the letter, be sure to include the manuscript's title and authors, as well as the submission type. The letter should also provide confirmation that the work is original, has not been previously published except as a brief abstract or as a preprint (please see the journal's preprint policies for more detail), and is not under consideration for publication elsewhere. Finally, the letter should also confirm that all authors have read and approved the manuscript and its related files, and all authors have approved its submission to The FASEB Journal.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);

A short running title of less than 50 characters;

The full names of the authors;

The author's institutional affiliations where the work was conducted, including city(ies)/province(s), and country (ies), with a footnote for the author’s present address if different from where the work was conducted;

A complete mailing address, email address and telephone number for the corresponding author;

Nonstandard abbreviations;

Acknowledgements;

Conflict of Interest statement;

Author contributions;

Abstract and keywords;

Main text (Introduction, Materials and Methods, Results, Discussion, Acknowledgments, Conflict of Interest, Author Contributions);

References;

Tables (each table complete with title and footnotes);

Figure legends;

Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

Title Page: The title page should contain:

The title of article, which should be concise, informative, accessible to the Journal's multidisciplinary readership, and generally free of acronyms and abbreviations;

The list of author(s), their affiliations with city(ies), state(s)/province(s), and country(ies);

A complete mailing address, an institutional email address, and telephone and fax numbers for the corresponding author; and

A short/running title (maximum of 50 characters and spaces).

Authorship

Please refer to the journal’s Author Contributions policy in the below section for details on author listing eligibility.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Nonstandard abbreviations: The second page should be a list of nonstandard abbreviations used in the manuscript. The journal does not provide a list of standard abbreviations, and the editors leave it to the judgment of the authors to determine which abbreviations are nonstandard. When composing your list, however, keep in mind that the journal is read by a multidisciplinary audience. Submissions lacking an abbreviations list will be returned to authors for correction.

Abstract

Please provide a brief abstract of no more than 250 words containing the major keywords and should generally cover the purpose of the study, methods, results and conclusions of the paper.

Keywords

Please provide 3-5 keywords. Keywords should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh.

Main Text:

The journal uses US spelling; however, authors may submit using British spelling, as British spelling of accepted papers is converted during the production process.

Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

The main text for Research and Methods articles should be divided into the following headings:

Research Articles

Introduction-The Introduction briefly summarizes the background of the research to be reported and should elaborate any theoretical background to the design of the experiments; it should not summarize the data.

Materials and Methods-The Materials and Methods section is an essential part of a full research report. It should contain the experimental protocols and describe the origin of any unusual or special materials, tissue, cell lines, or organisms. It is appropriate in this section to provide data to support the identity or purity of reagents, the reliability of methods, the sensitivity of an instrument, or the essential features of a genotype. Materials and Methods should either be thoroughly described in the manuscript or referenced in the literature. The Materials and Methods section of a manuscript should be comprehensive. Others must be able to replicate the experiments described in this section without having to access the manuscript’s supplemental data (primers essential to replicating experiments also must be included in the Materials and Methods section). At any stage in a manuscript’s review or post-acceptance publication process, a paper with supplemental files containing information essential to replicate experiments can be rejected as an incomplete submission or returned to authors for revision.

Companies mentioned in this section should include the name of the company, the company's city, state/province, and country (example: FASEB, Bethesda, MD, USA). Authors should put most of the experimental detail into the Materials and Methods section, leaving the Results section for exposition of the experimental design and results.

The FASEB Journal encourages the use of Research Resource Identifiers (RRIDs), which have been developed in support of NIH's guidelines for rigor and transparency in biomedical publications. RRIDs may be included with other, required, information in the Materials and Methods section, but may not be used as a substitute. Readers without access to RRID information must have enough information to replicate experiments. For more information about RRIDs, visit https://scicrunch.org/resources.

Results-The Results section should present, in logical order, the experiments that support the conclusions stated later in the Discussion. Particular care should be taken in the Results section to state results exactly; this is not the place for interpretations, extended lines of inference, arguments, or speculations.

Discussion-The Discussion section is where authors to propose their interpretation of their results and to suggest what they might mean in a larger context.

Methods Articles

Introduction: The Introduction briefly provides the background/context necessary for a multi/transdisciplinary audience understand the importance of the method.

Method: This section should contain the full experimental materials and protocols involved. The use of section and/or subsection headers in this part of the article is at the discretion of the authors. Nevertheless, this portion of the article should be complete enough for any reader to replicate what is described. Companies mentioned in this section should include the name of the company, the company's city, state/province, and country (example: FASEB, Bethesda, MD, USA). The authors should also be sure to provide information on key parameters such as the identity and purity of reagents, the sensitivity and precision (and accuracy when a true value is known) of methods, the sensitivity of  instruments, or biological information such as the cell lines or strains/genotypes of animals if key to the reported method. Finally, The FASEB Journal encourages the use of Research Resource Identifiers (RRIDs), which have been developed in support of NIH's guidelines for rigor and transparency in biomedical publications. RRIDs may be included with the other required information (see above) but may not be used as a substitute. Readers without access to RRID information must have enough information to replicate experiments. For more information about RRIDs, visit https://scicrunch.org/resources.

For the methods category, no procedural details should be included as supplemental data, but the editors will consider waiving this in rare and unusual cases.

Discussion: The authors should describe potential applications of the reported method (beyond the particular example given in the “Method” section itself) and should also describe any pitfalls or other limitations, as well as offering trouble-shooting advice if warranted. If applicable, the authors should also describe the advantages and disadvantages of the method described to other comparable methods. In situations where the methods described are completely novel, the authors should make this clear.  In cases where the method is being claimed to be superior to existing ones, the authors must make a compelling case.

Supplemental Data: Supplemental data for Methods articles is discouraged and generally not accepted. Methods article submissions containing supplemental data will be returned to authors for correction prior to review.

Acknowledgments:

The Acknowledgment section should include the following: (a) Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor. People who have contributed intellectually to the paper but whose contributions do not justify authorship may be named and their function or contribution described. Such persons must have given their permission to be named. Authors are responsible for obtaining written permission from persons acknowledged by name; and (b) acknowledgments and disclosures of financial and material support.

Conflict of Interest Statement:

Authors should include information on potential conflicts of interest in this section. Submitting authors should ensure that they liaise with all co-authors to confirm agreement with the final statement. If one or more authors has no conflicts to declare, this should be stated. Authors of research articles are required at the time of submission to disclose any potential conflict of interest (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) and that they accept full responsibility for the conduct of the study, had full access to all the data, and controlled the decision to publish. Failure to do so may jeopardize eventual publication. Such potential conflict, unless already disclosed in the submitted article, will be held in confidence while the paper is under review. If the article is accepted for publication, information on the potential conflict of interest will be included in the acknowledgments section of the article.

It is required that all articles include a Conflict of Interest Statement, regardless of whether or not a conflict of interest exists – for example, “The authors have stated explicitly that there are no conflicts of interest in connection with this article.”

Author Contributions:

The Author Contributions section should present the contributions of each author listed on the manuscript. Most contributions will fall within the following general designations:

Designed research

Performed research

Contributed new reagents or analytic tools

Analyzed data

Wrote the paper

When an author has made more than one type of contribution, he or she must disclose all contributions. It also is likely that more than one author will have similar/same contribution types. Finally, the list of contribution types is a suggestion. Authors should also disclose any additional and appropriate types of intellectual contributions made to the work.

Example:

Author Contributions

Smith and J. Q. Jones designed research; R. Thomas and J. P. Jones analyzed data; M. McGuinness, T. Adams, J. Q. Jones, J. P. Jones, E. Evans, and L. Heigl performed research; S. Smith, J. Q. Jones, and E. Evans wrote the paper; R. Thomas contributed new reagents or analytic tools; and N. Neumann developed software necessary to perform and record experiments.

References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals.

For more information about this reference style, please see the AMA Manual of Style.

Reference examples follow:

Journal article

King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book

Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.

Internet Document

American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003.

Endnotes and Footnotes

Endnotes and footnotes should be avoided. If necessary, include this information in parentheses.

Tables and Table Legends

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, in common word processing format, not pasted as images or in PDF format. Do not imbed tables as part of a figure. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings. Do not include citations in table legends. Any information in a table legend requiring citation must be communicated in the main body of the article.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

Images in computer generated figures may be processed only minimally (color balance, contrast, brightness), and only if applied to all parts of the figure equally. Descriptions of all adjustments must be provided in the manuscript. Specific components within images may not be edited in any way. Composite figures from multiple sources must indicate so in the figure legend and must include reference to the original sources. Data files must be retained by the authors and be provided upon request by the editor. Failure to provide unprocessed data files may result in manuscript rejection. Multi-panel figures must be submitted as they should be arranged should the paper be accepted for publication. Submitting each figure panel separately will lead to significant delays in the peer review process as well as the publication process.

Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Color figures. Figures submitted in color may be reproduced in color online free of charge. Please note, however, that it is preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they are legible if printed by a reader in black and white.

Data Citation

Please review Wiley’s data citation policy here.

Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Supplemental Information

Supplemental information is information that is not essential to the article but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include text, tables, figures, videos, datasets, etc.

These data must be well presented and written in clear and concise English expository prose. Video, audio and/or interactive media must be well produced and edited. Supplemental data that has been published previously in ANY form for ANY amount of time IS NOT permitted. This includes, but is not limited to, supplemental data that has been published as part of a full manuscript, as part of another manuscript’s supplemental data, or as “stand alone” information on a web site. Authors also may not submit supplemental data that are under consideration for publication elsewhere.

Units meant to supplement the Materials and Methods section of the manuscript MAY NOT contain information essential for others to replicate the experiments. All information essential to replicate the experiments described in the manuscript MUST be included in the manuscript. Please see the journal’s requirements for the Materials and Methods section (described above) before submitting supplemental data. Supplemental units containing points of discussion, interpretation, or opinion are not permitted. These items must be included in the main body of the manuscript.

Submissions that do not meet the requirements for supplemental data may be immediately rejected by the editors or returned to the authors for correction at any stage in the review or post-acceptance production processes.

Authors may submit up to 10 units of supplemental data per manuscript, but exceptions to this limit can be made by the Editor-in-Chief on a case-by-case basis. To request a waiver from the 10-unit limit on supplemental data, email journals@faseb.org. A supplemental data unit is defined as one 8.5 x 11 inch page of text or figures with 1 inch margins using Times New Roman, Courier, Arial, Calibri, and/or Tahoma fonts at 9 points or larger. For multimedia files (i.e. audio or video), each file is considered one unit. No unit may exceed 25 megabytes in size, and all supplemental units must be clearly labeled as such within the unit file itself, in the submission system, and in the file name. Supplemental data, including legends, etc., may not be included in the submitted article’s manuscript or figure files unless authors are specifically instructed to incorporate this information into a revised manuscript by a reviewer or an editor during the revision process. Authors may not submit supplemental data in compressed file formats (i.e. .zip, .bin, .cab, etc.). If the manuscript is accepted for publication, supplemental data will not be copy edited or laid out. Authors will not receive a “proof” for supplemental data.

Supplemental units will be published on The FASEB Journal’s web site as they were uploaded into the submission system, making it imperative that authors pay close attention to spelling, grammar, punctuation, and other important details. Revisions to supplemental data after manuscript acceptance are discouraged and additional author charges may apply when such requests are made.

Click here for Wiley’s FAQs on supplemental information.

Note: if data, scripts, or other artifacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website for more information about SI units.

Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).

Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Resource Identification Initiative

The Journal supports the Resource Identification Initiative, which aims to promote research resource identification, discovery, and reuse. This initiative, led by the Neuroscience Information Framework and the Oregon Health & Science University Library, provides unique identifiers for antibodies, model organisms, cell lines, and tools including software and databases. These IDs, called Research Resource Identifiers (RRIDs), are machine-readable and can be used to search for all papers where a particular resource was used and to increase access to critical data to help researchers identify suitable reagents and tools.

Authors are asked to use RRIDs to cite the resources used in their research where applicable in the text, similar to a regular citation or Genbank Accession number. For antibodies, authors should include in the citation the vendor, catalogue number, and RRID both in the text upon first mention in the Methods section. For software tools and databases, please provide the name of the resource followed by the resource website, if available, and the RRID. For model organisms, the RRID alone is sufficient.

Additionally, when RRIDs are used, authors must include them in the list of keywords associated with the manuscript. RRIDs do not count toward the limit of seven key words. To Obtain Research Resource Identifiers (RRIDs):

Use the Resource Identification Portal, created by the Resource Identification Initiative Working Group.

Search for the research resource (please see the section titled “Search Features and Tips” for more information).

Click on the “Cite This” button to obtain the citation and insert the citation into the manuscript text.

If there is a resource that is not found within the Resource Identification Portal, authors are asked to register the resource with the appropriate resource authority. Information on how to do this is provided in the “Resource Citation Guidelines” section of the Portal.

If any difficulties in obtaining identifiers arise, please contact rii-help@scicrunch.org for assistance.

Example Citations:

Antibodies: "Wnt3 was localized using a rabbit polyclonal antibody C64F2 against Wnt3 (Cell Signaling Technology, Cat# 2721S, RRID: AB_2215411)"

Model Organisms: "Experiments were conducted in c. elegans strain SP304 (RRID:CGC_SP304)"

Cell lines: "Experiments were conducted in PC12 CLS cells (CLS Cat# 500311/p701_PC-12, RRID:CVCL_0481)"

Tools, Software, and Databases: "Image analysis was conducted with CellProfiler Image Analysis Software, V2.0 (http://www.cellprofiler.org, RRID:nif-0000-00280)"

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, we encourage authors to consult Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation, and Formatting Support: Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief or Associate Editor determines that the paper meets the appropriate quality and relevance requirements.

In-house submissions, i.e. papers authored by Editors or Editorial Board members of the title, will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias. After receipt of a manuscript by the Editor-in-Chief, it may be sent to an Associate Editor who sends the manuscript to an appropriate number of reviewers (usually two, depending on the type of manuscript). Editors may ask for suggested reviewer names from an Editorial Board Member. Comments from reviewers are examined by the Editor-in-Chief and/or Associate Editors, who make the final decisions. Rebuttals should be addressed to the Editor-in-Chief at journals@faseb.org.

All reviewers remain unknown to the authors. Every manuscript is treated by the Editors and reviewers as privileged information, and they are instructed to exclude themselves from review of any manuscript that might involve a conflict of interest or the appearance thereof.

Upon submission of a manuscript, authors must suggest five potential reviewers who have not seen the manuscript before submission. Authors may request disqualification of up to four potential reviewers. Only those individuals who would represent a direct conflict of interest should be excluded. Authors cannot make an extensive or blanket disqualification of a group of possible reviewers, e.g., all potential competitors in one or more industrial laboratories or academic departments. Requests to disqualify reviewers will be honored at the discretion of the Editor assigned to the manuscript.

Revised Manuscript Submissions: Pending appropriate revisions requested by the Editors and/or reviewers, some manuscripts will be acceptable for publication in The FASEB Journal. When uploading the revised version, authors should include in the cover letter an itemized list of all changes made, or a rebuttal, in response to each of the suggestions.

Figures included with revisions will be used in the final version of the published article and they should be publication quality. When revising manuscripts, create each figure as a separate file saved as a TIFF, EPS, PPT, or PDF.

The FASEB Journal's production team will attempt to use the most recently submitted materials to prepare articles for publication. For manuscripts accepted for publication pending appropriate revisions, authors are strongly encouraged to provide preferred file formats for production at the next stage of review. The preferred format for text files is Microsoft Word, but RTF files are also acceptable. The preferred formats for figure files are TIF, EPS, PowerPoint, or PDF (if made from the original file format). Please see figure specifications for details on image preparation. Do not embed figures in the manuscript file. If the authors do not provide review files in these formats, the manuscript may be returned for correction prior to review.

Accepted Submissions: Once a manuscript receives final acceptance from the editors, it is scheduled for the next available issue and prepared for publication. For further information regarding the post-acceptance process please refer to the PUBLICATION PROCESS AFTER ACCEPTANCE section below.

If you have any questions regarding the preparation of your manuscript or the publication of your work, please contact journals@faseb.org.

Guidelines on Publishing and Research Ethics in Journal Articles

Please review Wiley’s policies surrounding human studies, animal studies, clinical trial registration, biosecurity, and research reporting guidelines here.

Human Studies and Subjects

Although the journal does not generally report medical studies that involve human participants, exceptions may occur. In these instances, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE 2.0 guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.

UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).

European authors outside the UK should conform to Directive 2010/63/EU.

Clinical Trial Registration

Although the journal generally does not publish reports of clinical trials, exceptions may occur. If/when applicable, the journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Scientific Misconduct Investigations

The FASEB Journal only accepts research papers that are original works, no part of which has been published or is being considered for publication elsewhere except as brief abstracts. Duplicate publication, falsification, plagiarism, or fabrication will be considered actionable misconduct. Misconduct does not include honest error or honest differences in interpretations or judgments of data.

The FASEB Journal recognizes its responsibility to ensure that the suspicion of misconduct has been addressed, but the Journal does not make such determinations and does not accept anonymous accusations.

If there is a suspicion or allegation of misconduct directed toward any author, The FASEB Journal reserves the right to forward relevant material to the appropriate authorities at the corresponding author's institution for investigation. The Journal also reserves the right to request (1) an acknowledgment from the corresponding author's institution that the matter will be reviewed appropriately; (2) full contact information for the individual responsible for handling the investigation of this matter at the corresponding author's institution; and (3) individually submitted signed statements from ALL authors acknowledging that they are aware of the allegation(s) and that the matter has been submitted to the appropriate office within the corresponding author's institution.

The FASEB Journal also believes that once allegations have been raised about a manuscript, they must be resolved to the satisfaction of an author's institutional review and not to the satisfaction of the accused or accuser. Therefore, the Journal will not accept requests to "retract" allegations made toward an author or manuscript.

Furthermore, The FASEB Journal understands that such investigations may take a significant amount of time, but it must balance the need for a comprehensive and fair investigation against its obligations to inform the readership that an article is in dispute. When allegations are not investigated and resolved quickly (within 3 months) and in a satisfactory manner, the Journal reserves the right to publish a notice of concern detailing the allegations, our requests for review, and any responses (or lack thereof) from the author(s) and their institution(s).

In situations where the corresponding author's institution refuses to comply with the Journal's request for investigation, the Journal will contact the appropriate officials at the institutions of the other authors to request an investigation. The Journal also will publish a statement of concern to inform its readership of the situation as well as the reasons given, if any, by the corresponding author's institution as to why there was no investigation.

If scientific misconduct is confirmed by institutional review, the Editor-in-Chief will report this to FASEB's Publications and Communications Committee (PCC) Chair and the FASEB Executive Director. Appropriate action will be decided in consultation with the FASEB Office of Publications. Violations considered severe may warrant official withdrawal of a published article or rapid rejection of a manuscript at any stage before publication. If no scientific misconduct is found, the manuscript (if unpublished) will be scheduled for publication. For errors in a published article not deemed to be misconduct, an Erratum will be published. If there is a disagreement about the results of the investigation, the Editor-in-Chief reserves the right to restrict the author(s) from publishing in the Journal for a specified period of time.

Editor Responsibilities

The Editor-in-Chief is responsible for the specific editorial conduct of The FASEB Journal and compliance with the relevant policies and procedures. When a report of suspected misconduct has been sent to the Editor-in-Chief, the following course of action will be taken. If the manuscript has yet to be published, all work on the manuscript will stop. No immediate action on already-published material (such as retracting an online pre-print article) will be taken until the matter is resolved. In cases of minor issues, the Editor-in-Chief will contact the corresponding author directly. In cases of major issues, the Editor-in-Chief will inform the PCC Chair of the accusation through the Director of Publications. If necessary, the Editor-in-Chief may supply copies to the PCC of 1) the relevant material and 2) a draft letter to the corresponding author asking for an explanation in a nonjudgmental manner. In some cases, the Editor-in-Chief may contact all the authors listed on the manuscript. Should the corresponding author's response fail to resolve the situation satisfactorily, the Editor-in-Chief will contact all the institutions of the contributing authors. The institutions should then make an inquiry and report back to the Editor-in-Chief. Until the matter is clarified, no papers by any authors on the disputed manuscript will be considered for publication.

Authors Involved in Misconduct on Multiple Articles in The FASEB Journal

If authors are found to have been involved in misconduct involving two or more articles published in The FASEB Journal either in the same or separate investigations, these authors will not be permitted to submit or publish in the Journal for an indefinite period of time at the discretion of the Editor-in-Chief. These authors may also be prohibited permanently from submitting or publishing papers in the Journal. In addition, the editorial office will take inventory of all papers published in the Journal by the author(s) and will submit all articles to the corresponding author's institution for a comprehensive audit. Specifically, the Journal will request that the institution examine: (1) the authenticity of the data presented in each article, (2) the validity of each person listed on the article's claim to authorship, and (3) any other items or terms appropriate given the context of previous misconduct findings.

Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used. 

Data Archiving Policy

Once an article has been published in The FASEB Journal, the editors and editorial board strongly encourage authors to archive the original data sets in publicly available and permanent repositories whenever possible and appropriate. The Journal makes no recommendation or suggestion as to which repositories are most appropriate but encourages authors to identify those which best meet their needs as well as the needs of those who will be accessing the data.

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

DNA Data Bank of Japan (DDBJ): ddbj.nig.ac.jp

EMBL Nucleotide Archive: ac.uk/ena

GenBank: ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories:

Protein Information Resource (PIR): georgetown.edu

SWISS-PROT: ch/sprot/sprot-top

Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: consultancies, patent or stock ownership, patent-licensing arrangements, equity interests, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this in the Conflict of Interest statement. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. 

……


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭

投稿有问题?问问网友吧!

问答